These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33657135)

  • 21. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
    Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
    Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
    Esparza TJ; Martin NP; Anderson GP; Goldman ER; Brody DL
    Sci Rep; 2020 Dec; 10(1):22370. PubMed ID: 33353972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
    Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
    Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
    Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
    J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of
    Ye G; Gallant J; Zheng J; Massey C; Shi K; Tai W; Odle A; Vickers M; Shang J; Wan Y; Du L; Aihara H; Perlman S; LeBeau A; Li F
    Elife; 2021 Aug; 10():. PubMed ID: 34338634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis.
    Zupancic JM; Desai AA; Schardt JS; Pornnoppadol G; Makowski EK; Smith MD; Kennedy AA; Garcia de Mattos Barbosa M; Cascalho M; Lanigan TM; Tai AW; Tessier PM
    Cell Chem Biol; 2021 Sep; 28(9):1379-1388.e7. PubMed ID: 34171229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
    Huang WC; Zhou S; He X; Chiem K; Mabrouk MT; Nissly RH; Bird IM; Strauss M; Sambhara S; Ortega J; Wohlfert EA; Martinez-Sobrido L; Kuchipudi SV; Davidson BA; Lovell JF
    Adv Mater; 2020 Dec; 32(50):e2005637. PubMed ID: 33111375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes.
    Mikolajek H; Weckener M; Brotzakis ZF; Huo J; Dalietou EV; Le Bas A; Sormanni P; Harrison PJ; Ward PN; Truong S; Moynie L; Clare DK; Dumoux M; Dormon J; Norman C; Hussain N; Vogirala V; Owens RJ; Vendruscolo M; Naismith JH
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2205412119. PubMed ID: 35858383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.
    Chen F; Liu Z; Kang W; Jiang F; Yang X; Yin F; Zhou Z; Li Z
    BMC Infect Dis; 2024 Feb; 24(1):199. PubMed ID: 38350843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
    Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    Front Immunol; 2022; 13():820336. PubMed ID: 35663966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2.
    Li T; Zhou B; Li Y; Huang S; Luo Z; Zhou Y; Lai Y; Gautam A; Bourgeau S; Wang S; Bao J; Tan J; Lavillette D; Li D
    Int J Biol Macromol; 2022 Jun; 209(Pt A):1379-1388. PubMed ID: 35460753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding.
    Lin S; Chen Z; Zhang X; Wen A; Yuan X; Yu C; Yang J; He B; Cao Y; Lu G
    Signal Transduct Target Ther; 2022 Feb; 7(1):56. PubMed ID: 35190526
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
    Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L
    Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.
    Tang Q; Owens RJ; Naismith JH
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
    Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
    J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.